BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 36197593)

  • 1. Antibody-Drug Conjugates in Non-Small Cell Lung Cancer: Emergence of a Novel Therapeutic Class.
    Marks JA; Wilgucki M; Liu SV; Reuss JE
    Curr Oncol Rep; 2022 Dec; 24(12):1829-1841. PubMed ID: 36197593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).
    Parisi C; Mahjoubi L; Gazzah A; Barlesi F
    Cancer Treat Rev; 2023 Jul; 118():102572. PubMed ID: 37230055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach.
    Marks S; Naidoo J
    Lung Cancer; 2022 Jan; 163():59-68. PubMed ID: 34923203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.
    Verma S; Breadner D; Raphael J
    Curr Oncol; 2023 Apr; 30(4):4329-4350. PubMed ID: 37185443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC).
    Abuhelwa Z; Alloghbi A; Nagasaka M
    Cancer Treat Rev; 2022 May; 106():102393. PubMed ID: 35472631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.
    Desai A; Abdayem P; Adjei AA; Planchard D
    Lung Cancer; 2022 Jan; 163():96-106. PubMed ID: 34942494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody Drug Conjugates in Lung Cancer.
    Merle G; Friedlaender A; Desai A; Addeo A
    Cancer J; 2022 Nov-Dec 01; 28(6):429-435. PubMed ID: 36383905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments.
    Reuss JE; Gosa L; Liu SV
    Clin Lung Cancer; 2021 Nov; 22(6):483-499. PubMed ID: 34420859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy.
    Liu X; Deng J; Zhang R; Xing J; Wu Y; Chen W; Liang B; Xing D; Xu J; Zhang M
    Front Immunol; 2023; 14():1335252. PubMed ID: 38162667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-drug conjugates in advanced lung cancer: Is this a new frontier?
    Reuss JE; Rosner S; Levy BP
    Clin Adv Hematol Oncol; 2024 Jun; 22(5):217-226. PubMed ID: 38805313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress.
    Rosner S; Valdivia A; Hoe HJ; Murray JC; Levy B; Felip E; Solomon BJ
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e389968. PubMed ID: 37163707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel antibody-drug conjugate, HcHAb18-DM1, has potent anti-tumor activity against human non-small cell lung cancer.
    Huhe M; Lou J; Zhu Y; Zhao Y; Shi Y; Wang B; Sun X; Zhang X; Zhang Y; Chen ZN
    Biochem Biophys Res Commun; 2019 Jun; 513(4):1083-1091. PubMed ID: 31010682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Research Progress of Antibody-drug Conjugates in Advanced Non-small Cell Lung Cancer].
    Wang N; Zhao L; Zhang D; Jia Y; Kong F
    Zhongguo Fei Ai Za Zhi; 2022 Mar; 25(3):214-218. PubMed ID: 35340165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies.
    Passaro A; Jänne PA; Peters S
    J Clin Oncol; 2023 Jul; 41(21):3747-3761. PubMed ID: 37224424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-drug conjugates in solid tumors: a look into novel targets.
    Criscitiello C; Morganti S; Curigliano G
    J Hematol Oncol; 2021 Jan; 14(1):20. PubMed ID: 33509252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors.
    Nelson BE; Meric-Bernstam F
    Annu Rev Med; 2024 Jan; 75():31-48. PubMed ID: 37758237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current Progress and Future Developments of Antibody Drug Conjugates 
in Lung Cancer].
    Zhu Y; Wang Z
    Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):468-476. PubMed ID: 35899443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-drug conjugates in HER2-positive breast cancer.
    Li L; Zhang D; Liu B; Lv D; Zhai J; Guan X; Yi Z; Ma F
    Chin Med J (Engl); 2021 Dec; 135(3):261-267. PubMed ID: 34935688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.